Val (EU) xit: do we need an international ISPOR value flower?
Publication: Journal of Comparative Effectiveness Research
Formats available
You can view the full content in the following formats:
References
1.
Goring S, Garrison LP, Jansen JP, Briggs AH. Novel elements of the value flower: fake or truly novel? Value Outcomes Spotlight 7(2), 34–39 (2021).
2.
Sanders GD, Neumann PJ, Basu A et al. Recommendations for conduct, methodological practices, and reporting of cost–effectiveness analyses: second panel on cost–effectiveness in health and medicine. JAMA 316(10), 1093–1103 (2016).
3.
Neumann PJ, Garrison LP, Willke RJ. The history and future of the “ISPOR Value Flower”: addressing limitations of conventional cost–effectiveness analysis. Value Health 25(4), 558–565 (2022).
4.
Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force Report [3]. Value Health 21(2), 131–139 (2018).
5.
Breslau RM, Cohen JT, Diaz J, Malcolm B, Neumann PJ. A review of HTA guidelines on societal and novel value elements. Int. J. Technol. Assess. Health Care 39(1), e31 (2023).
6.
Lakdawalla D, Malani A, Reif J. The insurance value of medical innovation. J. Public Econ. 145, 94–102 (2017).
7.
Kamal-Bahl S, Willke RJ, Puckett JT, Doshi JA. The case for using novel value elements when assessing COVID-19 vaccines and therapeutics. Health Aff. Forefr. (2020).
8.
Schaffer SK, West P, Towse A, Henshall C, Mestre-Ferrandiz J, Fischer A. Assessing the value of new antibiotics: additional elements of value for health technology assessment decisions. Office for Health Economics (2017). https://www.ohe.org/news/assessing-value-new-antibiotics-additional-elements-value-health-technology-assessment/
9.
Chan MS, Holloway R, King R et al. An insurance value modeling approach that captures the wider value of a novel antimicrobial to health systems, patients, and the population. J. Health Econ. Outcomes Res. 10(2), 1–9 (2023).
10.
Yuasa A, Yonemoto N, Demiya S, Foellscher C, Ikeda S. Investigation of factors considered by health technology assessment agencies in eight countries. PharmacoEconomics Open 5(1), 57–69 (2020).
11.
Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost–effectiveness assessments of high-cost cancer therapies. Health Aff. Proj. Hope 31(4), 676–682 (2012).
12.
Peasgood T, Mukuria C, Rowen D, Tsuchiya A, Wailoo A. Should we consider including a value for “hope” as an additional benefit within health technology assessment? Value Health 5(9), 1619–1623 (2022).
13.
Garrison LP, Zamora B, Li M, Towse A. Augmenting cost–effectiveness analysis for uncertainty: the implications for value assessment-rationale and empirical support. J. Manag. Care Spec. Pharm. 26(4), 400–406 (2020).
14.
Wong WB, To TM, Li M, Lee W, Veenstra DL, Garrison LP. Real-world evidence for option value in metastatic melanoma. J. Manag. Care Spec. Pharm. 27(11), 1546–1555 (2021).
15.
di Ruffano LF, Harris IM, Zhelev Z et al. Health technology assessment of diagnostic tests: a state of the art review of methods guidance from international organisations. Int. J. Technol. Assess. Health Care 39(1), e14 (2023).
16.
Asher D, Dai D, Klimchak AC, Sedita LE, Gooch KL, Rodino-Klapac L. Paving the way for future gene therapies: a case study of scientific spillover from delandistrogene moxeparvovec. Mol. Ther. Methods Clin. Dev. 30, 474–483 (2023).
17.
Wittenberg E, James LP, Prosser LA. Spillover effects on caregivers' and family members' utility: a systematic review of the literature. Pharmacoeconomics 37(4), 475–499 (2019).
18.
Cookson R, Griffin S, Norheim OF, Culyer AJ. Distributional cost–effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs. Oxford University Press, UK (2020).
19.
Aaskoven MS, Kjaer T, Gyrd-Hansen D. Effects of parental health shocks on children's school achievements: a register-based population study. J. Health Econ. 81, 102573 (2022).
20.
Fazel S, Zetterqvist J, Larsson H, Långström N, Lichtenstein P. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet 384(9949), 1206–1214 (2014).
21.
The Shift Project. Décarboner la santé pour soigner durablement (2023). https://theshiftproject.org/article/decarboner-sante-rapport-2023/
22.
McAlister S, Morton RL, Barratt A. Incorporating carbon into health care: adding carbon emissions to health technology assessments. Lancet Planet. Health 6(12), e993–e999 (2022).
23.
World Economic Forum. An economic analysis of the value of genetic testing. (2021). https://www3.weforum.org/docs/WEF_An_Economic_Analysis_of_the_Value_of_Genetic_Testing_2021.pdf
24.
Neumann PJ, Cohen JT, Hammitt JK et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 21(3), 238–251 (2012).
25.
Poudel N, Ngorsuraches S. A preference-based value assessment of the fear of COVID-19 contagion. Patient Prefer. Adherence 17, 3435–3448 (2023).
26.
Taylor M, Chilton S, Ronaldson S, Metcalf H, Nielsen JS. Comparing increments in utility of health: an individual-based approach. Value Health 20(2), 224–229 (2017).
27.
Mulligan K, Baid D, Doctor JN, Phelps CE, Lakdawalla DN. Risk preferences over health: empirical estimates and implications for healthcare decision making. Natl Bureau Economic Res. 94, 102857 (2023).
28.
Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ. 28(7), 855–867 (2019).
29.
Cadham CJ, Prosser LA. Eliciting trade-offs between equity and efficiency: a methodological scoping review. Value Health 26(6), 943–952 (2023).
30.
Xie RZ, Towse A, Garrison LP. Should we pay for scientific knowledge spillovers? The underappreciated value of “failed” R&D efforts. Int. J. Technol. Assess. Health Care 38(1), e31 (2022).
31.
“Our policy on cancer drugs” (2017). https://www.cancerresearchuk.org/about-us/we-develop-policy/our-policy-on-access-to-cancer-treatments/our-policy-on-cancer-drugs
32.
Park JY, Marcum ZA, Garrison LP. Toward a broader concept of societal value: family spillovers in Alzheimer's disease. Int. J. Technol. Assess. Health Care 38(1), e7 (2021).
33.
Al-Janabi H, Wittenberg E, Donaldson C, Brouwer W. The relative value of carer and patient quality of life: a person trade-off (PTO) study. Soc. Sci. Med. 1982 292, 114556 (2022).
34.
Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 8(1), e016982 (2018).
35.
Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333(7557), 15 (2006).
36.
Public Health England. Cost of Ill Health (2016). https://www.gov.uk/government/publications/health-matters-health-and-work/health-matters-health-and-work
37.
Maksymowych WP, Gooch KL, Wong RL, Kupper H, Heijde DVD. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J. Rheumatol. 37(2), 385–392 (2010).
Information & Authors
Information
Published In
Copyright
© 2024 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 14 May 2024
Accepted: 1 July 2024
Published online: 19 July 2024
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Val (EU) xit: do we need an international ISPOR value flower?. (2024) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0083
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Sreeram V Ramagopalan, Annie Jullien Pannelay, Access in all areas? A round-up of developments in market access and health technology assessment: part 15, Journal of Comparative Effectiveness Research, 10.57264/cer-2026-0111, 15, 8, (2026).